These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 26634965)

  • 1. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease.
    Bramlage P; Swift SL; Thoenes M; Minguet J; Ferrero C; Schmieder RE
    Eur J Heart Fail; 2016 Jan; 18(1):28-37. PubMed ID: 26634965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction.
    Lima-Posada I; Stephan Y; Soulié M; Palacios-Ramirez R; Bonnard B; Nicol L; Kolkhof P; Jaisser F; Mulder P
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.
    Liu LC; Schutte E; Gansevoort RT; van der Meer P; Voors AA
    Expert Opin Investig Drugs; 2015; 24(8):1123-35. PubMed ID: 26095025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
    Pitt B; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Nowack C; Kim SY; Pieper A; Kimmeskamp-Kirschbaum N; Filippatos G
    Eur J Heart Fail; 2015 Feb; 17(2):224-32. PubMed ID: 25678098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis.
    Pei H; Wang W; Zhao D; Wang L; Su GH; Zhao Z
    Medicine (Baltimore); 2018 Apr; 97(16):e0254. PubMed ID: 29668577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease.
    Lima Posada I; Soulié M; Stephan Y; Palacios Ramirez R; Bonnard B; Nicol L; Pitt B; Kolkhof P; Mulder P; Jaisser F
    J Am Heart Assoc; 2024 Jun; 13(12):e032971. PubMed ID: 38842271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, on Cardiovascular Disease, Chronic Kidney Disease, and Blood Pressure.
    Ravid JD; Laffin LJ
    Curr Cardiol Rep; 2022 Oct; 24(10):1251-1259. PubMed ID: 35925515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
    Pandey AK; Bhatt DL; Cosentino F; Marx N; Rotstein O; Pitt B; Pandey A; Butler J; Verma S
    Eur Heart J; 2022 Aug; 43(31):2931-2945. PubMed ID: 35713973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease.
    Barrera-Chimal J; Gerarduzzi C; Rossignol P; Jaisser F
    Clin Sci (Lond); 2022 Jun; 136(12):1005-1017. PubMed ID: 35765983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
    Kolkhof P; Delbeck M; Kretschmer A; Steinke W; Hartmann E; Bärfacker L; Eitner F; Albrecht-Küpper B; Schäfer S
    J Cardiovasc Pharmacol; 2014 Jul; 64(1):69-78. PubMed ID: 24621652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.
    Amazit L; Le Billan F; Kolkhof P; Lamribet K; Viengchareun S; Fay MR; Khan JA; Hillisch A; Lombès M; Rafestin-Oblin ME; Fagart J
    J Biol Chem; 2015 Sep; 290(36):21876-89. PubMed ID: 26203193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems.
    Kolkhof P; Lawatscheck R; Filippatos G; Bakris GL
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.
    Lv R; Xu L; Che L; Liu S; Wang Y; Dong B
    Front Endocrinol (Lausanne); 2023; 14():1125693. PubMed ID: 36860374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice.
    Bonnard B; Pieronne-Deperrois M; Djerada Z; Elmoghrabi S; Kolkhof P; Ouvrard-Pascaud A; Mulder P; Jaisser F; Messaoudi S
    J Mol Cell Cardiol; 2018 Aug; 121():124-133. PubMed ID: 29981797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finerenone: First Approval.
    Frampton JE
    Drugs; 2021 Oct; 81(15):1787-1794. PubMed ID: 34519996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
    Marzolla V; Infante M; Armani A; Rizzo M; Caprio M
    Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes.
    Kintscher U
    Curr Cardiol Rep; 2023 Dec; 25(12):1859-1864. PubMed ID: 37991625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.
    Filippatos G; Pitt B; Agarwal R; Farmakis D; Ruilope LM; Rossing P; Bauersachs J; Mentz RJ; Kolkhof P; Scott C; Joseph A; Bakris GL; Anker SD;
    Eur J Heart Fail; 2022 Jun; 24(6):996-1005. PubMed ID: 35239204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of the Non-Steroidal Mineralocorticoid Antagonist Finerenone in Cardiorenal Management.
    Beavers CJ
    Curr Cardiol Rep; 2022 Dec; 24(12):1785-1790. PubMed ID: 36272052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.